Single-cell analysis links DCUN1D5 to immune remodeling and cisplatin resistance in recurrent osteosarcoma
Abstract Cisplatin is the primary chemotherapeutic agent for osteosarcoma. However, a significant proportion of patients develop resistance post-treatment, leading to disease recurrence and presenting profound clinical challenges. To understand the mechanisms underlying osteosarcoma recurrence and c...
Saved in:
| Main Authors: | Xin Wu, Woding Deng, Qiangqiang Zhao, Jianbin Xiong |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Communications Biology |
| Online Access: | https://doi.org/10.1038/s42003-025-08409-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate in neoadjuvant treatment of resectable osteosarcoma: A prospective, single‐arm, exploratory phase II trial
by: Qinglian Tang, et al.
Published: (2024-09-01) -
A Dual Approach with Organoid and CRISPR Screening Reveals ERCC6 as a Determinant of Cisplatin Resistance in Osteosarcoma
by: Ruiling Xu, et al.
Published: (2025-07-01) -
Treatment strategies of recurrent jaw osteosarcoma: case report
by: O. A. Saprina, et al.
Published: (2023-12-01) -
Antitumor Effects of Hesperidin and Cisplatin on Human Osteosarcoma Cells Through Inhibiting Proliferation and Inducing Mitochondrial-Mediated Apoptosis
by: Mehmet Onur Ziyadanoğulları, et al.
Published: (2025-05-01) -
GLIPR1 modulates the response of cisplatin-resistant human lung cancer cells to cisplatin.
by: Xin Gong, et al.
Published: (2017-01-01)